Opus Genetics, Inc.
Business
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases, and other ophthalmic therapies. The company's pipeline includes seven adeno-associated virus-based gene therapy programs led by OPGx-LCA5 and OPGx-BEST1, plus Phentolamine Ophthalmic Solution for mydriasis, presbyopia, and low-light vision disturbances. Geographic focus spans U.S. and international markets; commercialization of Phentolamine is partnered with Viatris in most territories, while gene therapies are in clinical development.
Summary from 10-K filed 2026-03-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| License and collaborations revenue | 14 | 11 | 19 | 40 | 589,000 | |
| Research and development | 31 | 27 | 18 | 14 | 15 | |
| General and administrative | 22 | 18 | 12 | 7 | 8 | |
| Acquired in-process research and development | 0 | 28 | 0 | — | — | |
| Total operating expenses | 53 | 73 | 30 | 22 | 23 | |
| Loss from operations | −39 | −62 | −11 | 18 | −23 | |
| Fair value change in warrant and other derivative liabilities | −12 | 72,000 | 80,000 | 0 | −34 | |
| Financing costs (Note 7) | −1 | 0 | −1 | 0 | — | |
| Interest expense | −129,000 | 0 | — | — | — | |
| Other income, net | 2 | 4 | 2 | −14,000 | −157,000 | |
| Loss before income taxes | −50 | −58 | −10 | 18 | −57 | |
| Provision for income taxes | 0 | 0 | −12,000 | −315,000 | 0 | |
| Net loss | −50 | −58 | −10 | 18 | −57 | |
| Other comprehensive loss, net of tax | 0 | 0 | 0 | 0 | 0 | |
| Comprehensive loss | −50 | −58 | −10 | 18 | −57 | |
| Basic (in dollars per share) | −0.8 | −2.15 | −0.46 | 0.9 | −3.82 | |
| Diluted (in dollars per share) | −0.8 | −2.15 | −0.46 | 0.87 | −3.82 | |
| Basic (in shares) | 62 | 27 | 22 | 20 | 15 | |
| Diluted (in shares) | 62 | 27 | 22 | 21 | 15 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 45 | 30 | 51 | 43 | 25 | |
| Accounts receivable | 2 | 4 | 926,000 | 1 | 0 | |
| Contract assets and unbilled receivables (Note 10) | 1 | 2 | 1 | 4 | — | |
| Prepaids and other current assets | 2 | 515,000 | 1 | 1 | 1 | |
| Short-term investments | 0 | 2,000 | 15,000 | 49,000 | 219,000 | |
| Total current assets | 50 | 37 | 54 | 49 | 26 | |
| Property and equipment, net | 199,000 | 252,000 | 0 | 6,000 | 10,000 | |
| Total assets | 50 | 37 | 54 | 49 | 26 | |
| Accounts payable | 3 | 3 | 2 | 1 | 2 | |
| Accrued expenses and other liabilities | 4 | 8 | — | — | — | |
| Total current liabilities | 8 | 11 | 4 | 3 | 4 | |
| Warrant liabilities | 26 | 0 | — | — | — | |
| Funding agreement, related party | 1 | 0 | — | — | — | |
| Total liabilities | 35 | 11 | 4 | 3 | 4 | |
| Commitments and contingencies (Note 3 and Note 9) | — | — | — | — | — | |
| Series A preferred stock, par value $0.0001; no shares and 14,146 shares were designated as of December 31, 2025 and 2024, respectively; no shares and 14,145.374 shares issued and outstanding at December 31, 2025 and 2024, respectively. | 0 | 19 | 0 | — | — | |
| Preferred stock, par value $0.0001; 10,000,000 and 9,985,854 shares authorized as of December 31, 2025 and 2024, respectively; no shares issued and outstanding at December 31, 2025 and 2024. | 0 | 0 | 0 | 0 | 0 | |
| Common stock, par value $0.0001; 125,000,000 authorized as of December 31, 2025 and 2024; 69,894,507 and 31,574,657 shares issued and outstanding at December 31, 2025 and 2024, respectively. | 7,000 | 3,000 | 2,000 | 2,000 | 2,000 | |
| Additional paid-in capital | 204 | 146 | 131 | 118 | 112 | |
| Accumulated deficit | −189 | −139 | −81 | −71 | −89 | |
| Total stockholders' equity | 15 | 7 | 50 | 46 | 22 | |
| Total liabilities, Series A preferred stock, and stockholders' equity | 50 | 37 | 54 | 49 | 26 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 3 | 3 | 4 | 2 | 2 | |
| Depreciation | 53,000 | 10,000 | 6,000 | 4,000 | 4,000 | |
| Warrant Financing costs | 1 | 0 | — | — | — | |
| Non-cash share issuances | 57,000 | 0 | — | — | — | |
| Unrealized loss from short-term investments | 2,000 | 13,000 | 34,000 | 170,000 | 70,000 | |
| Gain in connection with asset acquisition | 0 | −2 | 0 | — | — | |
| Accounts receivable | 2 | −3 | 372,000 | −1 | 0 | |
| Contract assets and unbilled receivables | 1 | −802,000 | 2 | −4 | — | |
| Prepaid expenses and other assets | −1 | 634,000 | 354,000 | −139,000 | −45,000 | |
| Accounts payable | 7,000 | 220,000 | 1 | −515,000 | 381,000 | |
| Accrued expenses and other liabilities | −3 | 6 | 123,000 | −51,000 | −155,000 | |
| Net cash used in operating activities | −35 | −26 | −1 | 14 | −19 | |
| Cash received in connection with asset acquisition | 0 | 1 | 0 | — | — | |
| Net cash provided by investing activities | 0 | 1 | 0 | 0 | −100,000 | |
| Proceeds from issuance of common stock and pre-funded warrants in connection with the registered direct offering | 23 | 0 | — | — | — | |
| Proceeds from issuance of common stock and pre-funded warrants in connection with the March 2025 offering and March 2025 private placement | 6 | 0 | — | — | — | |
| Proceeds from issuance of warrants in connection with the March 2025 offering and March 2025 private placement | 16 | 0 | — | — | — | |
| Proceeds from issuance of common stock | 6 | 4 | 9 | 4 | 28 | |
| Issuance costs attributed to equity instruments | −2 | −232,000 | −278,000 | −131,000 | −2 | |
| Proceeds from funding agreement, related party | 1 | 0 | — | — | — | |
| Share repurchases for the payment of employee taxes | −152,000 | −79,000 | 0 | — | — | |
| Exercise of warrants | 820,000 | 0 | — | — | — | |
| Exercise of stock options | 352,000 | 0 | 30,000 | 27,000 | 87,000 | |
| Net cash provided by financing activities | 50 | 4 | 9 | 4 | 28 | |
| Net increase (decrease) in cash and cash equivalents | 15 | −20 | 8 | 18 | 8 | |
| Cash paid for income taxes | 0 | 0 | 344,000 | 0 | 0 | |
| Cash paid for interest | 0 | 0 | 0 | 9,000 | 2,000 | |
| Common stock and Series A preferred stock issued in connection with the asset acquisition | 0 | 26 | 0 | — | — | |
| Net liabilities assumed in connection with asset acquisition | 0 | 955,000 | 0 | — | — | |
| Conversion of Series A preferred stock into common stock | 19 | 0 | — | — | 0 | |
| Reclass of warrant liabilities to equity upon exercise | 1 | 0 | — | — | — | |
| Change in unpaid issuance costs | 24,000 | 163,000 | 10,000 | 2,000 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Opus Genetics, Inc.'s CIK number?
Opus Genetics, Inc.'s SEC CIK number is 0001228627 (1228627). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Opus Genetics, Inc.'s SEC filings?
All of Opus Genetics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Opus Genetics, Inc. last report earnings?
Opus Genetics, Inc. (IRD) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-033856). This is Opus Genetics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Opus Genetics, Inc.'s most recent earnings 8-K?
Opus Genetics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001628280-26-033856. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Opus Genetics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →